William Skach News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gene Therapy Market Insights, Growth Projection, Future Trends, Size Estimation and Industry Outlook by 2027

Gene Therapy Market Insights, Growth Projection, Future Trends, Size Estimation and Industry Outlook by 2027

In our final episode, we explore Dorothy Andersen’s legacy—what she left behind and how her work has lived on since her death. Describing her mentor’s influence on her life and career, Dr. Celia Ores gives us a rare look into what Dr. Andersen was really like. We then turn to researchers, doctors, and patients, who fill us in on the progress that has grown from Dr. Andersen’s initial work. These major developments include the discovery of the cystic fibrosis gene, the tremendous impact of the drug Trikafta, and the potential of lifesaving gene editing te...

When physician and pathologist Dorothy Andersen confronted a slew of confounding infant deaths, she suspected the accepted diagnosis wasn’t right. Her medical sleuthing led to the world’s understanding of cystic fibrosis, a disease that affects the lungs, the pancreas and a host of other organs. But she is by no means a household name. Who was this scientist, and how did she come to quietly make such an important medical contribution? This is the Lost Women of Science  podcast

Published: May 13, 2021 By Mark Terry   closed on a $28.5 million Series B financing round. Participating in the round were OrbiMed, Israel Biotech Fund, Integra Holdings, and the The company plans to use the money to advance its pipeline, including SPL84-23, an Anti Sense Oligonucleotide (ASO) product designed to completely restore Cystic Fibrosis Transmembrane conductance Regulator (CFTR) channel function in patient-derived cell cultures. SpliSense is planning to launch a Phase I/IIa trial in 2022. Cystic fibrosis (CF) is caused by mutations in the CFTR gene, which codes for the...